English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 858602      Online Users : 624
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version

    Collection

    期刊論文 [327/330]
    圖書 [1/1]
    會議論文/會議摘要 [115/179]

    Community Statistics


    近3年內發表的文件:74(14.51%)
    含全文筆數:443(86.86%)

    文件下載次數統計
    下載大於0次:443(100.00%)
    下載大於100次:424(95.71%)
    檔案下載總次數:176904(3.30%)

    最後更新時間: 2024-11-28 13:36

    Top Upload

    Loading...

    Top Download

    Loading...

    RSS Feed RSS Feed
    Jump to a point in the index:
    Or type in a year:
    Ordering With Most Recent First Show Oldest First

    Showing items 151-160 of 510. (51 Page(s) Totally)
    << < 11 12 13 14 15 16 17 18 19 20 > >>
    View [10|25|50] records per page

    DateTitleRelation
    2019-04-08 Predominant global glomerulosclerosis in patients of upper urinary tract urothelial carcinoma with pre-existing renal function impairment is a predictor of poor renal outcomes BMC Cancer. 2019 Apr 8;19:Article number 337.
    2019-03 A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens Gastric Cancer. 2019 Mar;22(2):344-354.
    2019-03 Foreword Hepatobiliary Surgery and Nutrition. 2019 Mar;8(Suppl. 1):S1.
    2019-02 ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling Oncogene. 2019 Feb;38(8):1340-1353.
    2019-02 ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling [Erratum: Oncogene. 2019 Feb;38(8):1340-1353.] Oncogene. 2019 Feb;38(8):1354.
    2019-02 Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (attraction-4) Annals of Oncology. 2019 Feb;30(2):250-258.
    2019-02 NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors European Journal of Cancer. 2019 Feb;108:78-87.
    2019-02 Mutational landscape by targeted next-generation sequencing in EBV-associated lymphoepithelioma-like cholangiocarcinoma Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 269.
    2019-02 A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naive, advanced, or metastatic biliary tract cancer (BTC) Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 319.
    2019-02 Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2 Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 8.

    Showing items 151-160 of 510. (51 Page(s) Totally)
    << < 11 12 13 14 15 16 17 18 19 20 > >>
    View [10|25|50] records per page

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback